What is Epi proColon
Epi proColon is the first and only screening tool for colorectal cancer that is blood based. The test helps to detect a marker in blood plasma (Septin 9) specific to colorectal cancer. A small blood sample is required for the screening. After analyzing the sample at a diagnostic laboratory, the results are out within a week. Epi proColon has increased the participation rate for colorectal screening by giving them another option to get checked.
What is Colorectal Cancer?
Colorectal cancer is the third most common type of cancer in men and women in the United States. It is a cancer that starts in the colon or rectum. While digestion takes place, food moves through the stomach and small intestine into the colon. The job of the colon is to absorb water and nutrients from the food and store the waste matter (feces). The feces then proceeds to the rectum from the colon before it leaves the body.
Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Colorectal cancer often begins as a growth called a polyp, which can form on the inner wall of the rectum or colon. Over time they become cancerous. Removing these polyps can prevent colorectal cancer.
Recommended age for screening
Epi proColon is recommended for people age 50 and older who are at average-risk for colorectal cancer and who are unwilling or unable to be screened by FIT or colonoscopy.
As a consequence, 60% of CRC cases are diagnosed when the cancer has already spread regionally or to distant organs and treatment becomes more challenging
Screening for colorectal cancer
In the US, 1 in 3, or 23 million eligible people are not screened for colorectal cancer. As a result, 60% of colorectal cancer patients are diagnosed when the cancer has already spread regionally or to distant organs. When colorectal cancer has spread in the body treatment becomes more challenging. Now with a blood sample screening available, the participation for colorectal screening may increase. The American Cancer Society has the target goal of reaching 80% of eligible Americans up to date for screening by 2018.
Colorectal Cancer detection rate
90% of colorectal cancer cases are curable if early screening is done and the cancer is still localized.
Recommended frequency of screening
An annual screening is recommended for colorectal cancer.
Epi proColon is the first and only FDA approved colorectal screening for people who are unable to be screened by colonoscopy.
Call Us to Get a Colorectal Screening Done
Polymedco CDP, LLC is the leading manufacturer, marketer, and distributor of clinical diagnostic test kits. We are the world leaders in non-invasive colorectal cancer screening technology. Call us if you want a screening done today. You can call us at 888 638 7757 or email at firstname.lastname@example.org.